Viewing
News|Videos|November 20, 2026

Why ST-100 is expanding from dry eye into corneal wound healing

Eric Schlumpf discusses why Stuart Therapeutics is taking vezocolmitide beyond dry eye disease and into corneal wound healing.

Stuart Therapeutics is expanding development of its lead candidate, vezocolmitide (ST-100; Stuart Therapeutics), beyond dry eye disease and into corneal wound healing. The company aims to pursue a class label in corneal wounds that would cover trauma, surgical, and other ocular surface indications. Vezocolmitide is investigational and has not been approved by the FDA for any indication.

Eric Schlumpf, president and chief executive officer of Stuart Therapeutics in Stuart, Florida, spoke with Ophthalmology Times about the expansion, which the company announced in October 2026 after submitting an investigational new drug (IND) application amendment to the FDA.1 Schlumpf explained that the corneal wound healing product will be dosed 4 times daily, compared with twice-daily dosing for the dry eye product.

What drove the move into corneal wounds?

According to Schlumpf, the opportunity grew out of the ocular surface healing results from the company's most recent phase 3 trial (NCT06178679),2 in which staining improved early on both the cornea and the conjunctiva. Vezocolmitide is a collagen mimetic peptide from the company's PolyCol platform,1 and Schlumpf said its collagen-reparative mechanism applies directly to some of the underlying causes of the difficulty physicians have in healing corneal wounds.

Physicians use fluorescein staining as the key measure of ocular surface damage because it shows breakdown of the corneal epithelium, Schlumpf noted. In the dry eye trial, patients received 1 dose in the evening after their baseline visit and another the morning of their day 2 visit, and Schlumpf said staining had improved substantially by that second visit.

On safety, Schlumpf described a very low adverse event rate. The drug is a synthesized polypeptide made of amino acids "that the body expects to see," he said, and the main tolerability issue has been minor stinging and burning upon instillation, which he described as typical for patients with a damaged ocular surface.

What comes next for vezocolmitide?

A registration trial of twice-daily vezocolmitide in dry eye disease is set to begin in the first half of 2027. For corneal wounds, the company plans a physician study to narrow the first indication and will meet with the FDA to discuss a phase 2 trial expected in the second half of 2027.1

Schlumpf said leading anterior segment surgeons and physicians in the US see the drug's mechanism of action as unique, and he pointed to slow relief with current dry eye options as a major gap. "Everyone has to wait a long time, and there's a lot of turnover in prescriptions because no one's real satisfied with the current state," he told Ophthalmology Times.

References
1. Stuart Therapeutics expands pipeline with corneal wound healing program. News release. Stuart Therapeutics. October 9, 2026. Accessed November 18, 2026. https://stuarttherapeutics.com/stuart-therapeutics-expands-pipeline-with-corneal-wound-healing-program/
2. Safety and efficacy of ST-100 (vezocolmitide) ophthalmic solution 60 μg/ml ophthalmic solution in subjects diagnosed with dry eye disease (DED). ClinicalTrials.gov identifier: NCT06178679. Updated January 18, 2024. Accessed November 18, 2026. https://clinicaltrials.gov/study/NCT06178679

Related to this article